36C25026P0534 BILATERALLY SIGNED.pdf

PAGE 1 OF1. REQUISITION NO.

2. CONTRACT NO. 3. AWARD/EFFECTIVE DATE 4. ORDER NO. 5. SOLICITATION NUMBER 6. SOLICITATION ISSUE DATE

a. NAME b. TELEPHONE NO. (No Collect Calls) 8. OFFER DUE DATE/LOCAL

TIME

9. ISSUED BY CODE 10. THIS ACQUISITION IS UNRESTRICTED OR SET ASIDE: % FOR:

SMALL BUSINESS

HUBZONE SMALL

BUSINESS

SERVICE-DISABLED

VETERAN-OWNED

SMALL BUSINESS

WOMEN-OWNED SMALL BUSINESS

(WOSB) ELIGIBLE UNDER THE WOMEN-OWNED

SMALL BUSINESS PROGRAM

EDWOSB

8(A)

NAICS:

SIZE STANDARD:

11. DELIVERY FOR FOB DESTINA-

TION UNLESS BLOCK IS

MARKED

SEE SCHEDULE

12. DISCOUNT TERMS

13a. THIS CONTRACT IS A

RATED ORDER UNDER

DPAS (15 CFR 700)

13b. RATING

14. METHOD OF SOLICITATION

RFQ IFB RFP

15. DELIVER TO CODE 16. ADMINISTERED BY CODE

17a. CONTRACTOR/OFFEROR CODE FACILITY CODE 18a. PAYMENT WILL BE MADE BY CODE

TELEPHONE NO. UEI: EFT:

PHONE: FAX:

17b. CHECK IF REMITTANCE IS DIFFERENT AND PUT SUCH ADDRESS IN OFFER

18b. SUBMIT INVOICES TO ADDRESS SHOWN IN BLOCK 18a UNLESS BLOCK BELOW IS CHECKED

SEE ADDENDUM

19. 20. 21. 22. 23. 24.

ITEM NO. SCHEDULE OF SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

(Use Reverse and/or Attach Additional Sheets as Necessary)

25. ACCOUNTING AND APPROPRIATION DATA 26. TOTAL AWARD AMOUNT (For Govt. Use Only)

27a. SOLICITATION INCORPORATES BY REFERENCE FAR 52.212-1, 52.212-4. FAR 52.212-3 AND 52.212-5 ARE ATTACHED. ADDENDA ARE ARE NOT ATTACHED.

27b. CONTRACT/PURCHASE ORDER INCORPORATES BY REFERENCE FAR 52.212-4. FAR 52.212-5 IS ATTACHED. ADDENDA ARE ARE NOT ATTACHED

28. CONTRACTOR IS REQUIRED TO SIGN THIS DOCUMENT AND RETURN _______________ 29. AWARD OF CONTRACT: REF. ___________________________________ OFFER COPIES TO ISSUING OFFICE. CONTRACTOR AGREES TO FURNISH AND DATED ________________________________. YOUR OFFER ON SOLICITATION DELIVER ALL ITEMS SET FORTH OR OTHERWISE IDENTIFIED ABOVE AND ON ANY (BLOCK 5), INCLUDING ANY ADDITIONS OR CHANGES WHICH ARE ADDITIONAL SHEETS SUBJECT TO THE TERMS AND CONDITIONS SPECIFIED SET FORTH HEREIN IS ACCEPTED AS TO ITEMS:

30a. SIGNATURE OF OFFEROR/CONTRACTOR 31a. UNITED STATES OF AMERICA (SIGNATURE OF CONTRACTING OFFICER)

30b. NAME AND TITLE OF SIGNER (TYPE OR PRINT) 30c. DATE SIGNED 31b. NAME OF CONTRACTING OFFICER (TYPE OR PRINT) 31c. DATE SIGNED

AUTHORIZED FOR LOCAL REPRODUCTION (REV. NOV 2021)

PREVIOUS EDITION IS NOT USABLE Prescribed by GSA - FAR (48 CFR) 53.212

7. FOR SOLICITATION

INFORMATION CALL:

STANDARD FORM 1449

SOLICITATION/CONTRACT/ORDER FOR COMMERCIAL PRODUCTS AND COMMERCIAL SERVICES

OFFEROR TO COMPLETE BLOCKS 12, 17, 23, 24, & 30

541-26-3-775-1139

36C25026P0534 AWARDED:

EFFECTIVE: 04-16-2026

Thomas Bellamy 317-988-1518

36C250 Department of Veterans Affairs Network Contracting Office 10 8888 Keystone Crossing Suite 325 Indianapolis IN 46240

X

621511

$41.5 Million

N/A

36C541

Department of Veteran Affairs Louis Stokes Cleveland VAMC

10701 East Blvd.

Cleveland OH 44106

36C250

Department of Veterans Affairs Network Contracting Office 10 8888 Keystone Crossing Suite 325 Indianapolis IN 46240

03CM6

MAYO COLLABORATIVE SERVICES, INC.

3050 SUPERIOR DR NW

ROCHESTER MN 55905

JWSMJMBLTN44

36C250

Department of Veterans Affairs Financial Management System P O Box 149971 Austin TX 78714-9971

512-242-7300 N/A

See CONTINUATION Page

Lab testing for Pathology & Laboratory Mgt Service (PALMS)

Period of Performance is 04/16/2026 thru 10/16/2026 Please refer to PO 541C60258 when submitting invoices via Tungsten Network:https://authentication.tungsten-network-com

$274,712.78 See CONTINUATION Page

541-3660160-775-822300-2560 0100J20P5

X

X X X 1

Thomas Bellamy 4-16-2026

36C25026P0534

Table of Contents

SECTION A

A.1 SF 1449 SOLICITATION/CONTRACT/ORDER FOR COMMERCIAL PRODUCTS

AND COMMERCIAL SERVICES

SECTION B - CONTINUATION OF SF 1449 BLOCKS

B.1 CONTRACT ADMINISTRATION DATA

B.2 PRICE/COST SCHEDULE

ITEM INFORMATION

ACCOUNTING AND APPROPRIATION DATA

SECTION C - CONTRACT CLAUSES

C.1 52.212-4 CONTRACT TERMS AND CONDITIONS—COMMERCIAL PRODUCTS

AND COMMERCIAL SERVICES (NOV 2023)

C.2 52.217-8 OPTION TO EXTEND SERVICES (NOV 1999)

C.3 52.240-91 SECURITY PROHIBITIONS AND EXCLUSIONS (NOV 2025)

(DEVIATION)

C.4 VAAR 852.232-72 ELECTRONIC SUBMISSION OF PAYMENT REQUESTS (NOV

2018)

C.5 VAAR 852.239-76 INFORMATION AND COMMUNICATION TECHNOLOGY

ACCESSIBILITY (FEB 2023)

C.6 VAAR 852.242-71 ADMINISTRATIVE CONTRACTING OFFICER (OCT 2020)

C.7 52.252-2 CLAUSES INCORPORATED BY REFERENCE (FEB 1998)

C.8 52.212-5 CONTRACT TERMS AND CONDITIONS REQUIRED TO IMPLEMENT

STATUTES OR EXECUTIVE ORDERS—COMMERCIAL PRODUCTS AND

COMMERCIAL SERVICES (OCT 2025) (DEVIATION FEB 2025)

SECTION D - CONTRACT DOCUMENTS, EXHIBITS, OR ATTACHMENTS

SECTION B - CONTINUATION OF SF 1449 BLOCKS

B.1 CONTRACT ADMINISTRATION DATA

1. Contract Administration: All contract administration matters will be handled by the following individuals:

a. CONTRACTOR: Mayo Collaborative Services

Mike Kampf

215-313-5277

Kampf.Mike@mayo.edu

b. GOVERNMENT: Contracting Officer 36C250 Thomas Bellamy

Department of Veterans Affairs

Network Contracting Office 10

8888 Keystone Crossing

Suite 325

Indianapolis IN 46240

2. CONTRACTOR REMITTANCE ADDRESS: All payments by the Government to the contractor will be made in accordance with:

[X] 52.232-33, Payment by Electronic Funds Transfer—System For Award Management, or

[X] 52.232-36, Payment by Third Party

3. INVOICES: Invoices shall be submitted in arrears:

a. Quarterly []

b. Semi-Annually []

c. Other [x] Monthly

4. GOVERNMENT INVOICE ADDRESS: All Invoices from the contractor shall be submitted electronically in accordance with VAAR Clause 852.232-72 Electronic Submission of Payment Requests.

Tungsten Network: https://www.tungsten-network.com/customer-campaigns/veteransaffairs.

ACKNOWLEDGMENT OF AMENDMENTS: The offeror acknowledges receipt of amendments to the Solicitation numbered and dated as follows:

AMENDMENT NO DATE

STATEMENT OF WORK (SOW)

as of March 26, 2026

Referral-Based Esoteric

Diagnostic Pathology Services

Contract Number: 36C25026P0534

Task Order Number: NA

IFCAP Tracking Number:

Follow-on to Contract and Task Order Number:

1. CONTRACTNG OFFICER’S REPRESENTATIVE (COR)

Name: Stephen Fakner

Section: Pathology & Laboratory Management Service

Address: 10701 East Boulevard Cleveland, Ohio 44106

Phone Number: 216-791-3800 x66188

Fax Number: N/A

E-Mail Address: Stephen.Fakner@va.gov

2. CONTRACT TITLE: Referral-Based Esoteric Diagnostic Pathology Services- Emergency Six

(6) Month Contract

3. BACKGROUND

The VA Northeast Ohio Healthcare System (VANEOHS) requires continued access to esoteric and referral laboratory testing services necessary for the diagnosis, treatment, and clinical management of Veterans receiving direct patient care.

Pathology diagnostic testing services are inherently patient-specific, clinically driven, and continuously evolving. These services are ordered based on individual Veteran presentation and provider medical judgment and cannot be reliably forecasted in advance. As such, the Government cannot reasonably define or predict, at the time of contract award:

The exact diagnostic tests required during the period of performance

The frequency or volume of testing

The specific methodologies that will be clinically appropriate at the time of service

The cost structure associated with advancements in diagnostic science

Testing demand is influenced by multiple variables, including:

Individual Veteran clinical presentation

Disease progression and acuity

Treatment response and monitoring requirements

Co-morbid conditions

Provider medical judgment and evolving standards of care

Clinical staffing and workload changes

As diagnostic science advances, individual tests may be replaced, expanded, or modified while maintaining the same clinical purpose. Accordingly, acquisition structures based on static or exhaustively itemized test lists are not compatible with the operational realities of esoteric diagnostic testing.

The VANEOHS Pathology and Laboratory Medicine Service (PALMS) is a fully accredited, high-complexity laboratory. However, certain esoteric tests cannot be performed in-house due to low testing volume, specialized instrumentation requirements, complex methodologies, and the need for subspecialty expertise.

Esoteric testing under this requirement includes highly specialized diagnostic services such as autoimmune neurology panels, molecular genetic testing, infectious disease sequencing, cytogenetics, specialized chemistry, and tissue-based diagnostics. These services support the identification of rare, complex, or multifactorial disease processes and are critical to completing diagnostic evaluations initiated by VA providers.

This requirement is being executed as an emergency six (6) month extension to prevent interruption of these services while a follow-on acquisition is completed. Interruption would result in delays in diagnosis, disruption of treatment, and increased clinical risk to Veterans.

Many diagnostic pathways require multi-step, reflex, or sequential testing, making continuity of services operationally and clinically critical.

In-House Capability and Need for Referral Testing:

The VANEOHS PALMS is a state-of-the-art, fully accredited laboratory service providing a comprehensive range of clinical laboratory and anatomic pathology services. The mission of PALMS is to deliver timely, accurate, and appropriate diagnostic services in direct support of Veteran patient care.

While PALMS maintains robust internal capabilities, certain autonomic and esoteric laboratory tests cannot be performed in-house due to one or more of the following factors:

Low testing volumes that do not justify in-house validation, staffing, and maintenance

Specialized or proprietary equipment requirements not available at the VANEOHS

Highly complex methodologies requiring subspecialty expertise

Referral-only assays available exclusively through tertiary laboratories

Workforce constraints, including vacant pathologist positions and increasing workload within Pathology

To ensure continuity of care and access to clinically necessary diagnostics, VANEOHS must rely on external referral laboratories, including the Mayo Clinic Laboratories, to perform specialized testing that cannot be reasonably completed in-house.

The requested requirement is being placed as a sole source procurement through the Mayo Clinic Laboratories. The Mayo Clinic Laboratories is uniquely positioned to provide the referral-based esoteric, and specialized pathology diagnostic services required under this requirement in an expeditious, clinically reliable, and operationally efficient manner.

4. SCOPE

This requirement encompasses referral-based laboratory diagnostic testing utilizing blood, urine, body fluid, tissue, and fecal specimens as applicable. Services include test performance, technical analysis, professional interpretation, and diagnostic correlation necessary to deliver complete, clinically actionable diagnostic results to VA providers.

The requirement is structured as a FFP contract due to the Government’s inability to predetermine patient-specific diagnostic needs, test types, methodologies, volumes, or future advancements in diagnostic science over the period of performance.

CLINs are organized by diagnostic capability categories, consistent with customary academic and commercial referral laboratory practice, rather than by individual CPT codes or discrete test itemization. CPT codes, where applicable, are used for invoicing and utilization reporting purposes only and do not define the scope of services being procured.

This requirement is for referral-based diagnostic laboratory services, not for the procurement of discrete supplies or standalone test items. Services are rendered in association with each diagnostic capability category (CLIN) and are performed on a patient-specific, case-by-case basis in direct support of clinical care.

Under this requirement, the Contractor shall provide specialized referral testing services necessary to complete, clarify, confirm, or refine diagnostic evaluations ordered by authorized VA providers. Services include the performance of testing, technical analysis, professional interpretation, diagnostic correlation, and reporting required to deliver complete, clinically actionable diagnostic results within the scope of each CLIN.

The scope of services is intentionally structured around diagnostic outcomes, rather than individual test names or billing descriptors, to reflect industry standards for referral and esoteric laboratory testing and to accommodate evolving methodologies throughout the period of performance. Testing may include specialized, proprietary, successor, or clinically equivalent assays offered by the referral laboratory that fall within the same diagnostic purpose, specimen scope, and clinical intent of the applicable CLIN.

All services performed under this contract are intended to support direct patient care, ensure continuity of diagnostic services not available in-house, and provide VA clinicians with the information necessary to make informed medical decisions. No tangible deliverables are required beyond the diagnostic services and results associated with each patient-specific referral.

General Requirements:

The Contractor shall provide referral-based clinical laboratory and anatomic pathology diagnostic services, including pre-analytic processing, analysis, professional interpretation, and reporting of results for specimens submitted by the VANEOHS, in support of direct patient care.

Services are service-based and rendered in association with authorized diagnostic capability categories (CLINs) established under this requirement.

Services include:

Pre-analytic processing and specimen requirements

Specimen handling, packaging, and transport coordination

Performance of specialized diagnostic testing

Technical analysis and professional interpretation

Reporting of clinically actionable results

Consultation and test utilization support

Ancillary and technical services necessary to complete diagnostic evaluations

Standards of Performance:

The Contractor shall perform all testing in accordance with applicable College of American Pathologists (CAP), and Clinical Laboratory Improvement Amendments (CLIA), as applicable.

Representative testing types anticipated under this contract are identified in contract Exhibits for planning and ceiling-estimation purposes. Due to the patient-specific and evolving nature of referral diagnostics, tests may vary over time and are not limited to a static list.

Time-Sensitive Testing and Billing Flexibility:

Some referral testing services are time-sensitive and cannot be delayed pending contract modification without negatively impacting patient care. The Contractor shall maintain the capability to:

Perform authorized diagnostic services that fall within the established CLIN structure

Submit invoices for such services in accordance with the contract’s pricing methodology

Support post-performance verification and reconciliation through the Government’s invoice review process

Supplies:

The Contractor shall provide all supplies necessary to perform referral testing, including but not limited to:

Specialized specimen containers

Chain-of-custody documentation (when required)

Shipping kits, manifests, and transport request forms

Transportation and Courier Services (Specimen):

VANEOHS shall be responsible for coordinating and providing reliable specimen transport services, including courier pickup and delivery.

The Contractor shall support specimen transport operations as needed. Responsibilities include:

Immediate notification of any identified discrepancies related to specimen receipt or transport conditions

Results Reporting and Data Access:

The Contractor shall provide secure, timely, and accessible reporting of diagnostic results, including:

Secure web-based portal access for ordering and result retrieval

Comment [JS1]: Acceptable as drafted

Comment [ST2]: Concur

Compatibility with VA electronic health record systems, including VistA and Cerner (as applicable)

Interim reporting via secure fax in the event of system unavailability

Advance notification (minimum 30 days) of test methodology or reference range changes

Reported results shall include, at a minimum:

Two patient identifiers

Ordering provider and facility

Specimen details and timestamps

Test performed and results

Reference ranges and abnormal flags

Interpretive comments, when applicable

The Contractor shall make reasonable efforts, in accordance with applicable industry standards and guidelines, to ensure critical values are communicated via direct telephone communication within two (2) hours of identification.

Customer Service and Clinical Consultation:

The Contractor shall provide 24/7/365 customer service support, including:

Specimen status inquiries

Test result clarification

Technical and methodological support

Test utilization guidance

Consultative services shall include:

Access to pathologists and medical directors

Diagnostic interpretation support

Assistance with appropriate test selection

Genetic counseling review of complex germline genetic testing orders

Response-time standards - the Contractor shall make reasonable efforts to comply with the following:

Routine inquiries: The Contractor shall acknowledge receipt of routine inquiries and make reasonable efforts to provide timely responses based on the nature and complexity of the request.

Utilization guidance: Within two (2) business days

Result interpretation: Within four (4) business hours

Clinical significance consultation: Within twenty-four (24) business hours

Reporting and Utilization Analysis:

The Contractor shall provide routine utilization and management reports upon request, including:

Monthly test volume summaries

Identification of ordering trends

Cost analysis to support fiscal oversight

Top send-out tests by volume and cost

Reports shall exclude PHI/PII and be accessible electronically for analysis and presentation purposes.

Specimen Retention, Slides, and Returns:

The Contractor shall:

Retain blood and fluid specimens in accordance with CAP and CLIA compliance policies

Store specimens under conditions that maintain viability

Return slides, blocks, and specimens upon request within established timeframes

Task Orders:

Services shall be ordered via task orders issued by the ordering activity in accordance with FAR Part 16, contract terms, and established CLIN structures.

Technical Requirements:

The Contractor shall maintain:

A broad referral test menu

Defined specimen requirements and turnaround times

All testing shall be performed within the United States, either by the Contractor or approved affiliates or subcontractors.

General Qualifications:

Licensing and Accreditation:

Laboratories must maintain active CAP and CLIA accreditation

All required licenses and certifications shall be current and unrestricted

Subcontractors must meet identical quality and accreditation standards

Personnel Qualifications:

Laboratory Director must be American Board of Pathology certified or equivalent

Contractor personnel shall maintain all required licenses

Contractor shall notify the CO of any licensure or certification issues within 24 hours

Experience Requirements:

Minimum four (4) years of laboratory diagnostic service experience

Minimum one (1) year experience in biomedical specimen transport

5. SPECIFIC TASKS

The Contractor shall provide esoteric referral laboratory diagnostic testing services across the following diagnostic categories, inclusive of primary, reflex, confirmatory, and successor testing methodologies, as clinically required to support patient-specific diagnostic evaluations within the VANEOHS. The representative tests identified under each task are provided for scope illustration and do not constitute an exhaustive or limiting list of services.

Diagnostic Capability-Based (CLIN):

Each CLIN represents a diagnostic service capability, not a closed or exhaustive list of individual tests. The representative tests identified under each CLIN are provided for descriptive purposes only.

Services under each CLIN include, but are not limited to, the listed tests and may also include any specialized, proprietary, successor, replacement, or clinically equivalent diagnostic tests offered by the referral laboratory that:

Fall within the same diagnostic purpose and clinical intent of the CLIN

Utilize the same general specimen types (blood, urine, fecal)

Are required to complete, clarify, confirm, or refine the diagnostic evaluation

Provide clinically meaningful values or interpretive results necessary for provider decision-making and patient care

This approach ensures that the contract supports the diagnostic outcome, rather than limiting care based on static test nomenclature, and allows adaptation to evolving laboratory methodologies without the need for frequent contract modifications.

AUTOIMMUNE NEUROLOGY AND PARANEOPLASTIC DIAGNOSTICS

Includes Tests Such As (But Not Limited To):

Antiglial/Neuronal Nuclear Antibody-Type 1 (AGNA-1) Antineuronal Nuclear Antibodies (ANNA-1, ANNA-2, ANNA-3) NMDA-Receptor, AMPA-Receptor, and GABA-B-Receptor Antibodies Myelin Oligodendrocyte Glycoprotein (MOG) Antibodies Aquaporin-4 (NMO) Antibodies CRMP-5, PCA, TRIM46, Septin-7, PDE10A Antibodies Autoimmune encephalopathy panels

What these provide:

Identification of immune-mediated neurologic disease, detection of paraneoplastic syndromes, differentiation of demyelinating conditions, and guidance for immunotherapy and oncology evaluation.

Additional Authorized Testing:

Includes additional autoimmune neurology and paraneoplastic diagnostic testing that serves the same clinical purpose, including expanded antibody panels, reflex confirmatory testing, titer-based evaluations, cell-based assays, and successor or platform-specific methodologies necessary to fully characterize immune-mediated neurologic conditions and provide a complete diagnostic result.

MOLECULAR GENETICS AND GENOMIC TESTING

Includes Tests Such As (But Not Limited To):

Marfan, Loeys-Dietz, and Ehlers-Danlos panels Hypertrophic cardiomyopathy gene panels Primary hemophagocytic lymphohistiocytosis panels MLH1 hypermethylation analysis Maternal cell contamination analysis Bioinformatics reanalysis

What these provide:

Detection of genetic mutations, confirmation of hereditary disease, risk stratification, and support for targeted treatment planning.

Additional Authorized Testing:

Includes additional molecular genetics and genomic diagnostic testing that serves the same clinical intent, including expanded gene panels, single-gene analysis, next-generation sequencing, deletion/duplication analysis, epigenetic testing, variant reclassification, and platform-specific or successor assays required to establish or refine a genetic diagnosis.

INFECTIOUS DISEASE AND MOLECULAR MICROBIOLOGY

Includes Tests Such As (But Not Limited To):

Broad-range bacterial PCR and sequencing Whole genome sequencing Candida auris molecular detection Meningitis/encephalitis pathogen panels Helicobacter pylori testing and resistance detection Joint infection PCR panels Histoplasma and Blastomyces antigen testing HPV detection with genotyping

What these provide:

Identification of infectious organisms, including rare or resistant pathogens, enabling accurate diagnosis and targeted treatment.

Additional Authorized Testing:

Includes additional infectious disease and microbiology diagnostics that serve the same clinical purpose, including expanded pathogen panels, multiplex PCR assays, sequencing-based identification, culture-independent diagnostics, resistance gene detection, reflex organism identification, and platform-specific or successor methodologies necessary to identify causative pathogens and support treatment decisions.

ANTIMICROBIAL SUSCEPTIBILITY TESTING

Includes Tests Such As (But Not Limited To):

Minimum inhibitory concentration (MIC) testing Mycobacterium tuberculosis susceptibility testing Nocardia and actinomycetes susceptibility testing Yeast susceptibility panels Aerobic and anaerobic bacterial susceptibility testing

What these provide:

Determination of effective antimicrobial therapy and identification of resistance patterns to support targeted treatment.

Additional Authorized Testing:

Includes additional antimicrobial susceptibility and resistance testing that serves the same diagnostic intent, including expanded susceptibility panels, resistance mechanism detection, phenotypic and genotypic resistance testing, reflex susceptibility testing, and platform-specific or successor assays required to guide effective antimicrobial therapy.

SPECIALIZED CLINICAL CHEMISTRY AND METABOLIC TESTING

Includes Tests Such As (But Not Limited To):

Antistrep-O Titer Beta-CrossLaps D-Lactate Fatty acid profile High-sensitivity Troponin I Monoclonal protein studies

What these provide:

Evaluation of metabolic disorders, systemic disease processes, and disease progression.

Additional Authorized Testing:

Includes additional specialized clinical chemistry and metabolic diagnostics that serve the same clinical purpose, including expanded metabolic panels, protein characterization studies, biomarker analysis, reflex testing, and platform-specific or successor assays required to assess biochemical abnormalities and disease progression.

CYTOGENETICS AND HEMATOPATHOLOGY

Includes Tests Such As (But Not Limited To):

Chronic eosinophilia diagnostic FISH panels

What these provide:

Detection of chromosomal abnormalities and hematologic malignancies, supporting diagnosis and prognosis.

Additional Authorized Testing:

Includes additional cytogenetic and hematopathology diagnostics that serve the same clinical intent, including expanded FISH panels, karyotyping, molecular cytogenetics, reflex genetic testing, and successor or platform-specific methodologies required to identify chromosomal abnormalities and hematologic disease processes.

TISSUE AND CELL-BASED TESTING

Includes Tests Such As (But Not Limited To):

Fibroblast culture for biochemical or molecular testing

What these provide:

Evaluation of rare genetic and metabolic disorders at the cellular level.

Additional Authorized Testing:

Includes additional tissue-based and cellular diagnostic testing that serves the same clinical purpose, including expanded culture-based assays, tissue-specific molecular testing, biochemical analysis, reflex testing, and platform-specific or successor methodologies necessary to evaluate cellular function and disease processes.

ANATOMIC PATHOLOGY SERVICES

Includes Tests Such As (But Not Limited To):

Immunohistochemistry (IHC) Special stains Tissue processing Gross and microscopic evaluation Morphologic analysis

What these provide:

Tissue-based diagnosis, cancer identification, and histologic confirmation.

Additional Authorized Testing:

Includes additional anatomic pathology and ancillary diagnostic services that serve the same clinical purpose, including expanded immunohistochemistry panels, advanced staining techniques, digital pathology analysis, reflex testing, and platform-specific or successor methodologies required to complete tissue-based diagnostic evaluations.

Miscellaneous, Successor, Pass through, & Emerging Esoteric Diagnostics:

This CLIN captures newly introduced, renamed, replacement, or successor referral diagnostic assays that arise during the period of performance solely because of industry-driven changes in test methodology, technology, or standard-of-care.

Authorized testing under this CLIN is strictly limited to diagnostic assays that:

Fall within the overall scope of this contract

Align with an existing authorized diagnostic capability category established under this requirement

Serve the same diagnostic purpose and clinical intent as testing already within scope

Utilize equivalent specimen types (blood, urine, fecal)

Are required to complete, clarify, confirm, or refine patient-specific diagnostic evaluations

This CLIN is not intended to expand the scope of services beyond the diagnostic categories defined in this contract. Rather, it exists to accommodate variation in test nomenclature, assay platforms, pass through tests required for patient specific diagnostic services, analytical methodologies, or industry standards that occur over time, including:

Replacement of obsolete tests

Introduction of successor assays with improved sensitivity or specificity

Platform-driven changes implemented by the referral laboratory

Pass through tests required for patient specific cases where the test is not available for completion through the referral laboratory

Standard-of-care updates affecting how existing diagnostic questions are evaluated

All testing performed under this CLIN must remain clinically and diagnostically equivalent to authorized testing categories and must support the delivery of complete, clinically actionable diagnostic results for provider interpretation and patient care.

What these provide:

Ensures continued access to updated and clinically accepted diagnostic technologies without disruption to patient care.

Deliverables:

The Contractor shall provide referral-based diagnostic laboratory services in support of each applicable CLIN to ensure the delivery of complete, accurate, and clinically actionable diagnostic results for Veterans receiving direct patient care.

Deliverables under this contract are service-based, not supply-based, and are rendered in association with each diagnostic capability category (CLIN). Deliverables include, but are not limited to, the following:

Performance of specialized referral laboratory testing within the scope of each CLIN, utilizing blood, urine, and fecal specimens as applicable

Technical analysis and processing of specimens in accordance with industry standards, accreditation requirements, and validated laboratory methodologies

Professional interpretation and diagnostic correlation necessary to support provider review and clinical decision-making

Reporting of diagnostic findings shall be provided in a format suitable for incorporation into the VA electronic health record or other authorized clinical systems

Clarification, confirmation, or refinement of diagnostic results when additional or successor testing is required to complete the diagnostic evaluation

Consultation or interpretive support associated with complex or esoteric test results, when required

Each delivery is intended to support the overall diagnostic outcome associated with the applicable CLIN and should be provided in a manner that ensures continuity of care, timeliness, and clinical reliability.

The Contractor shall not be required to deliver discrete physical products; rather, deliverables consist of diagnostic services and results necessary to complete the patient-specific diagnostic assessment ordered by authorized VA providers.

Exhibits – Representative Testing and Pricing Reference:

Purpose of Exhibits:

The contract includes one or more Exhibits that identify representative referral laboratory testing and diagnostic service types by test name or organized by diagnostic capability category. These Exhibits are provided for reference and planning purposes only and are not intended to serve as an exhaustive or fixed test menu, as referral testing often experiences changes or methodology and techniques during a period of performance.

The Exhibits are designed to support the Government’s understanding of the types of diagnostic services anticipated under this requirement and to assist in establishing reasonable not-to-exceed (NTE) ceilings for the contract and associated task orders.

Exhibit Content and Structure:

Each Exhibit may include, but is not limited to:

Representative test names commonly associated with each CLIN diagnostic category

General diagnostic service descriptions

Typical specimen types (e.g., blood, urine, fecal)

Indicative or estimated pricing information based on historical utilization, commercial reference data, or referral laboratory pricing structures

The Exhibits reflect diagnostic service categories, not guaranteed availability of specific tests, and are intended to illustrate the scope and nature of referral testing anticipated during the period of performance.

Exclusion of CPT-Level Itemization:

Specific CPT codes are intentionally omitted from the Exhibits and from the base contract CLIN structure. This omission is necessary due to the clinical, patient-specific nature of referral laboratory testing and the Government’s inability to reasonably predetermine:

Which specific tests will be clinically appropriate for individual patients

The frequency or volume of particular tests

Changes in test methodologies, platforms, or nomenclature over time

Annual or interim CPT code updates, reclassifications, or retirements

CPT codes, where applicable, may be utilized at the invoicing and reporting level only and do not define the scope of services authorized under the contract.

Role of Exhibits in Contract Administration:

The Exhibits are intended to function as reference tools, not contractual limitations. Specifically, the Exhibits shall be used to:

More fully identify the types of referral diagnostic services anticipated under each CLIN

Support Government planning and budgetary analysis

Establish and justify contract and task-order NTE ceilings

Facilitate invoice review and CLIN-level verification

Provide transparency into expected laboratory activity

The absence or presence of a specific test name within an Exhibit does not determine whether a service is authorized under the contract. Authorization is determined by whether the service:

Falls within the overall scope of the contract

Aligns with an authorized diagnostic capability category (CLIN)

Serves the same diagnostic purpose and clinical intent

Utilizes authorized specimen types

Pricing Schedule:

The Contractor shall provide a comprehensive Pricing Schedule at the time of contract award.

The Pricing Schedule shall:

Align with the overarching diagnostic CLIN categories and associated exhibits.

Identify unit pricing or pricing methodology for representative autonomic referral and esoteric laboratory tests.

Reflect the Contractor’s commercial pricing structure in effect at the time of award.

Serve as the baseline pricing reference for all orders issued during the Period of Performance.

The Pricing Schedule shall be incorporated into the contract as an attachment or exhibit under each associated CLIN and shall constitute the approved pricing framework for services performed under this agreement.

To ensure pricing transparency and contract administration integrity, the Contractor agrees that:

Unit pricing established at contract award shall remain valid for the duration of the contract period unless otherwise modified by bilateral contract modification.

Prices for testing services shall not be increased, restructured, or replaced

The Contractor shall not introduce alternative pricing methodologies, bundled charges, or revised fee structures that deviate from the approved Pricing Schedule without Government authorization.

6. Performance Monitoring

Invoice Review and Validation Process:

Invoices submitted under this requirement shall be reviewed using a multi-step verification process, which includes:

CLIN Validation:

Confirm each billed test is mapped to an authorized CLIN

Verify consistency with diagnostic scope and specimen type

Service Confirmation:

Validate that services were rendered and results provided

Confirm that professional interpretation and diagnostic correlation were included, where applicable

Clinical Alignment Review:

Ensure testing supports the documented clinical indication

Confirm that testing contributes to completion of the diagnostic evaluation

Pricing and Ceiling Review:

Validate pricing against approved contract rates or pricing methodology

Ensure cumulative charges remain within the requirement not-to-exceed (NTE) ceiling and applicable task order limits

Duplicate and Redundancy Check:

Confirm tests were not duplicative unless clinically justified

Validate add-on or reflex testing aligns with the original diagnostic intent

Contracting Officer’s Representative (COR) Oversight:

The Contracting Officer’s Representative (COR) shall provide ongoing oversight of services performed under this requirement to ensure compliance with contract scope, authorized diagnostic categories (CLINs), fiscal controls, and applicable VA policies.

COR oversight is focused on verification and administration of services, not clinical decision-making, and is intended to ensure that all referral laboratory services are rendered under this contract:

Fall within the authorized diagnostic capability categories (CLINs)

Support direct patient care based on valid provider orders

Are consistent with the scope and purpose of the requirement

Are properly invoiced and applied against the correct CLIN and contract ceiling

COR Responsibilities:

The COR shall be responsible for the following oversight functions:

Reviewing invoices to confirm that billed services align with authorized CLIN categories and diagnostic purposes

Verifying that services invoiced were rendered and that diagnostic results or interpretations were provided

Ensuring that testing performed under CLIN 0010 (Miscellaneous, Successor & Emerging Esoteric Diagnostics) represents authorized successor or equivalent testing and does not constitute scope expansion

In the event of scope expansion, the COR will notify the Contracting Officer that a modification is required to include a new testing category and reject the invoicing of that service.

Monitoring cumulative expenditures at the CLIN and contract level to ensure compliance with not-to-exceed (NTE) ceilings

Requesting clarification or supporting documentation from the Contractor when test categorization, scope alignment, or pricing requires validation

Identifying potential discrepancies, anomalies, or trends that may indicate inappropriate billing, duplication of services, or scope misalignment

7. Security Requirements

The C&A requirements do not apply, and the Security Accreditation package is not required for this SOW.

8. Government-Furnished Equipment (GFE)/Government-Furnished Information (GFI).

There will be no government-Furnished equipment of information.

9. Other Pertinent Information or Special Considerations.

The requested Video Integration upgrade shall be interoperable/usable with current workflows and technology deployed and used within the clinical atmosphere.

a. Identification of Possible Follow-on Work.

NA

b. Identification of Potential Conflicts of Interest (COI).

NA

c. Identification of Non-Disclosure Requirements.

NA

d. Packaging, Packing and Shipping Instructions.

NA

e. Inspection and Acceptance Criteria.

NA

10. Risk Control

NA

Place of Performance.

VA Northeast Ohio Healthcare System

Period of Performance.

Six (6) months upon award

B.2 PRICE/COST SCHEDULE

ITEM INFORMATION

ITEM

NUMBER

DESCRIPTION OF

SUPPLIES/SERVIC

ES QUANTITY UNIT UNIT PRICE AMOUNT

0001 1.00 EA $210.000000 $210.00

AGNBC: Antiglial/Neuronal Nuclear Antibody-Type 1, Immunoblot, Spinal Fluid Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$210.00

0002 1.00 EA $210.000000 $210.00

AGNBS: Antiglial/Neuronal Nuclear Antibody-Type,1 Immunoblot, Serum Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$210.00

0003 1.00 EA $95.000000 $95.00

AGNTC: Anti-Glial/Neuronal Nuclear Antibody-Type 1 (AGNA-

1) Titer, Spinal Fluid Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$95.00

0004 1.00 EA $95.000000 $95.00

AGNTS: Anti-Glial/Neuronal Nuclear Antibody-Type 1 (AGNA-

1) Titer, Serum Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$95.00

0005 1.00 EA $475.000000 $475.00

AINCC: Alpha Internexin, Cell Binding Assay, Spinal Fluid Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$475.00

0006 1.00 EA $475.000000 $475.00

AINCS: Alpha Internexin, Cell Binding Assay, Serum Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$475.00

0007 1.00 EA $210.000000 $210.00

AMIBC: Amphiphysin Antibody, Immunoblot, Spinal Fluid Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$210.00

0008 1.00 EA $210.000000 $210.00

AMIBS: Amphiphysin Antibody, Immunoblot, Serum Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$210.00

0009 1.00 EA $95.000000 $95.00

AMPIC: AMPA-Receptor Antibody Titer Assay by Immunofluorescence, Spinal Fluid Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$95.00

0010 1.00 EA $95.000000 $95.00

AMPIS: AMPA-Receptor Antibody Titer Assay, Immunofluorescence, Serum Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$95.00

0011 1.00 EA $210.000000 $210.00

AN1BC: Antineuronal Nuclear Antibody-Type 1, Immunoblot, Spinal Fluid Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$210.00

0012 1.00 EA $210.000000 $210.00

AN1BS: Antineuronal Nuclear Antibody-Type 1, Immunoblot, Serum Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$210.00

0013 1.00 EA $95.000000 $95.00

AN1TC: Antineuronal Nuclear Antibody-Type 1 (ANNA-1) Titer, Spinal Fluid Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$95.00

0014 1.00 EA $95.000000 $95.00

AN1TS: Antineuronal Nuclear Antibody-Type 1 (ANNA-1) Titer, Serum Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$95.00

0015 1.00 EA $210.000000 $210.00

AN2BC: Antineuronal Nuclear Antibody-Type 2, Immunoblot, Spinal Fluid Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$210.00

0016 1.00 EA $210.000000 $210.00

AN2BS: Antineuronal Nuclear Antibody-Type 2, Immunoblot, Serum Contract Period: Base POP Begin: 04-16-2026

POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$210.00

0017 1.00 EA $95.000000 $95.00

AN2TC: Antineuronal Nuclear Antibody Type 2 (ANNA-2) Titer, Spinal Fluid Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$95.00

0018 1.00 EA $95.000000 $95.00

AN2TS: Antineuronal Nuclear Antibody Type 2 (ANNA-2) Titer, Serum Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$95.00

0019 1.00 EA $95.000000 $95.00

AN3TC: Antineuronal Nuclear Antibody Type 3 (ANNA-3) Titer, Spinal Fluid Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$95.00

0020 1.00 EA $95.000000 $95.00

AN3TC: Antineuronal Nuclear Antibody Type 3 (ANNA-3) Titer, Serum Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$95.00

0021 1.00 EA $78.400000 $78.40

ANAID: Anaerobe Ident (Bill Only) Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$78.40

0022 1.00 EA $485.300000 $485.30

ANIDE: Organism Referred for Identification, Anaerobic Bacteria Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$485.30

0023 1.00 EA $95.000000 $95.00

APHTC: Amphiphysin Antibody Titer Assay, Spinal Fluid Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$95.00

0024 1.00 EA $95.000000 $95.00

APHTS: Amphiphysin Antibody Titer Assay, Serum Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$95.00

0025 2.00 EA $103.410000 $206.82

ASO: Antistrep-O Titer, Serum Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$206.82

0026 1.00 EA $89.400000 $89.40

BIORE: Bioinformatics Reanalysis (Bill Only) Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$89.40

0027 1.00 EA $39.400000 $39.40

BLA: Beta Lactamase (Bill Only) Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$39.40

0028 10.00 EA $434.500000 $4,345.00

BRBPS: Broad Range Bacterial PCR and Sequencing, Varies Contract Period: Base POP Begin: 04-16-2026 POP End: 10-16-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

ACRN: 1 Requisition Number: 541-26-3-775-1139

Appropriation: 541-3660160-775-822300 Laboratory-2560

MEDICAL CARE CONTRACTS AN-0100J20P5

$4,345.00

0029 2.00 EA $1,100.000000 $2,200.00

BTWGS: Bacterial Typing, Whole Genome Sequencing, Varies Contract Period: Base…